w10.0.6 | c9.
PROD | u7.5.14
Header Image service-corner


print content
increase font
decrease font

Eurofins Strengthens Its Footprint In Genomic Services With The Acquisition Of AROS AB

Additional Information


For further information contact:
Eurofins Investor Relations
Phone: +32-2-766 1620
Email: ir@eurofins.com

Further Information

Read more at eurofins.com.

Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the global market leaders in genomic services, announces the acquisition of AROS Applied Biotechnology A/S (AROS), a leading provider of genomic solutions in Europe, serving the pharmaceutical industry, as well as academic and public research institutes.

Founded in 2000 to provide GLP-approved genomic solutions to the pharmaceutical industry for the discovery and the development of new drugs, AROS generates revenues of about EUR 10m. It has strong relationships with large pharmaceutical companies and research institutes, and over the last couple of years, has built a leading position in Next-Generation Sequencing (NGS) for pharmaceutical research purposes, its main revenue growth engine. This competence is strategically aligned with Eurofins' strength as one of the largest commercial NGS providers in the world, through Eurofins Genomics. As one of the pioneering NGS providers,Eurofins Genomics is the preferred partner of many public and private research laboratories and institutions. The addition of AROS into its genomic services network reinforces Eurofins' position as a leading testing provider to the pharmaceutical industry, and expands its genomic services footprint into the Nordic region, in addition to its laboratories in Europe, US, India, and Japan.  It also complements Eurofins' technological platform with additional state-of-the-art capabilities in genotyping and expression profiling.

As part of the Eurofins Group, AROS will be able to increase its current capabilities in microarray analysis and next-generation sequencing to benefit its clients, and expand its market reach. The acquisition also provides AROS access to a broader portfolio of high-quality genomic services to further strengthen its position as a full service genomic service provider in its markets. Furthermore, the acquisition allows the Group to further expand its share of the high-growth NGS market targeted to the needs of the pharmaceutical industry by leveraging its increased scale.

Comment from Dr. Gilles Martin, Eurofins CEO: "AROS is an excellent strategic fit with Eurofins' genomic services business. It expands our geographical footprint for our genomics offering, and their competence is entirely consistent with our focus on high-quality next-generation sequencing. We remain committed to strengthening our market position in genomic services, as we believe that technological advancements in sequencing equipment will eventually enable mass-application of NGS across industries."

Scroll to top ^^